Aeolus Pipeline Initiative
Data presented here are unaudited and therefore subject to change
upon complete review. If changes need to be made they will be and a similar
notice will be posted.
The Aeolus Pipeline Initiative is an internal development initiative
focused on advancing several of the most promising catalytic antioxidant
compounds from Aeolus’ proprietary library of 200 compounds. The
initial therapeutic focus areas for the Aeolus Pipeline Initiative are:
- Parkinson’s disease
- Autoimmune disorders (arthritis and ulcerative colitis)
- Chronic obstructive pulmonary disease
- Biodefense / radioprotection
- Tumor suppression / bone marrow transplantation
- Stroke
These therapeutic focus areas were selected based upon preliminary data
developed using Aeolus catalytic antioxidant compounds, as well as both
the clinical path and the market sizes of therapeutics for these diseases.
In the near term, the Company expects to evaluate 24-30 compounds and
test up to 12 of these in animal models by the end of the fourth quarter
of this year, and the first quarter of next year. The goal is to then
select 1-2 of the most promising of these compounds and prepare these
for initiation of clinical evaluation in 2006, and then another 2-3 compounds
for initiation of clinical evaluation in 2007. In this manner, the Company
will be in the unique position to have multiple early stage clinical trials
proceeding while at the same time advancing compounds through efficacy
evaluation, either on its own or in conjunction with strategic partner(s).
Initial funding for the Aeolus Pipeline Initiative was recently secured
by the Company via a $2.5 million investment by existing institutional
shareholders of the Company. Approximately 95% of this funding is ear-marked
specifically for advancement of programs under the Aeolus Pipeline Initiative.
|
